RAPS

FDA Drafts 2 New Guidances on Effects of Food on Drugs, Bioavailability Studies

The US Food and Drug Administration (FDA) on Monday published two new draft guidance documents providing recommendations to sponsors planning to conduct food-effect (FE) studies for orally ...

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Detailed price information for Bionxt Solutions Inc. (BNXT-CN) from The Globe and Mail including charting and trades.
Nasdaq

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...
Nasdaq

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, ...
Morningstar

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Morningstar

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...